What are GLP-1 drugs and why are they important?

GLP-1 (glucagon-like peptide-1) drugs are medications that help regulate blood sugar and promote weight loss by mimicking a hormone naturally produced in your intestines. They're important because they treat both diabetes and obesity effectively, representing a multi-billion pound market opportunity for pharmaceutical companies.

Why is an oral version better than injections?

Oral GLP-1 drugs offer significant advantages over injections, including greater convenience, improved patient compliance, and reduced fear of needles. This convenience could dramatically expand the number of people willing to use these treatments, potentially growing the overall market size substantially.

What makes Eli Lilly's orforglipron breakthrough so significant?

Eli Lilly's successful Phase 3 trial of orforglipron represents the first major success in developing an effective oral GLP-1 drug. This breakthrough proves that oral alternatives to injections are possible and has intensified competition among pharmaceutical companies to develop their own oral versions.

What does 'Analyst Rating' mean for these stocks?

Analyst Rating refers to professional investment analysts' recommendations for each stock, typically ranging from 'Strong Buy' to 'Strong Sell'. These ratings are based on analysts' research into the company's financial health, market position, and growth prospects.

How risky are biotech and pharmaceutical investments?

Biotech and pharmaceutical investments can be higher risk because they depend on successful drug development, regulatory approval, and market acceptance. However, successful drugs can generate substantial returns. Companies at different development stages carry different risk levels, from early research (higher risk) to established market players (lower risk).

15 handpicked stocks

Beyond The Needle: The Oral GLP-1 Revolution

Eli Lilly's successful trial of its oral weight-loss drug, orforglipron, signals a major shift in the treatment landscape for obesity and diabetes. This theme focuses on the innovative pharmaceutical companies developing the next wave of convenient, non-injectable therapies poised to challenge the dominance of current market leaders.

Han Tan | Market Analyst

Updated today | Published at August 28